CliffBio
small molecule

CANASA

MESALAMINE

Loss of exclusivityJune 2028latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCANASA
Active ingredientMESALAMINE
Strength1GM
Dosage formSUPPOSITORY
RouteRECTAL
ModalitySmall molecule
FDA approvalNovember 2004
Marketing statusRX

Listed patents

PatentExpiresType
8217083June 2028product
8436051June 2028product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CANASA patent cliff — loss of exclusivity June 2028 | CliffBio